PPARA and diabetes mellitus: The recent Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) trial for Pemafibrate - a highly active and selective PPARα agonist - in diabetic patients [36] was stopped in April 2022.